Examkin

Question

Difficulty: HardHematology and Oncology

A hospitalised 68-year-old female is evaluated on postoperative day 6 following an elective right total knee arthroplasty. She reports new-onset pain and tightness in her right calf. She has been receiving subcutaneous unfractionated heparin for chemical thromboprophylaxis since her surgery. Vital signs are within normal limits. Physical examination reveals an erythematous, swollen right lower extremity with tenderness to palpation over the popliteal fossa. A venous duplex ultrasonography confirms an acute occlusive thrombus in the right popliteal vein. Laboratory studies show a current platelet count of 55,000/mm355,000/\text{mm}^3. Her preoperative baseline platelet count was 250,000/mm3250,000/\text{mm}^3. The patient has no history of liver disease or other bleeding disorders. Based on the calculated clinical probability score, arrange the following management steps in the correct chronological sequence for this patient.

  1. 1Immediate cessation of all unfractionated and low-molecular-weight heparin exposures
  2. 2Initiation of a non-heparin anticoagulant (e.g., argatroban or fondaparinux)
  3. 3Measurement of anti-platelet factor 4 (PF4) antibodies via enzyme-linked immunosorbent assay (ELISA)
  4. 4Confirmatory testing with a functional serotonin release assay (SRA)
  5. 5Transition to an oral vitamin K antagonist (e.g., warfarin)

Answer

The correct sequence for managing suspected high-probability heparin-induced thrombocytopenia (HIT) is to first discontinue all heparin, immediately initiate a non-heparin anticoagulant, perform diagnostic testing (screening ELISA followed by confirmatory functional assay), and finally transition to warfarin only after platelet counts have normalised.
In high-probability HIT, immediate cessation of all heparin and initiation of a non-heparin alternative anticoagulant (such as argatroban) are the most urgent interventions to prevent further clotting. Only after securing alternative anticoagulation should the diagnostic workup (PF4 ELISA, then functional SRA) proceed. Transitioning to long-term oral anticoagulation with warfarin is the final step, safely performed only once the platelet count has recovered completely.

Step-by-Step Solution

1
Calculate the 4T score to determine the clinical probability of HIT.
High probability (Score = 7).
The patient has a >50% platelet drop, occurring on day 6 of heparin therapy, with a new proven thrombosis, and no other clear cause for thrombocytopenia.
2
Stop the offending agent.
Discontinue all heparin-containing products.
Heparin acts as the required cofactor for the formation of the antigenic complexes with Platelet Factor 4 (PF4) that drive the autoimmune destruction and platelet activation.
3
Initiate alternative therapeutic anticoagulation.
Start argatroban, bivalirudin, or fondaparinux.
The patient is actively clotting (new popliteal DVT). Do not wait for laboratory confirmation before providing life-saving anticoagulation.
4
Proceed with the step-wise laboratory diagnosis.
Order the PF4 ELISA, followed by the Serotonin Release Assay (SRA) if the ELISA is positive.
The immunoassay is highly sensitive (good screening test) but lacks specificity. The functional SRA is the gold standard for confirmation.
5
Establish long-term anticoagulation.
Transition to warfarin only when platelets > 150,000/mm3150,000/\text{mm}^3.
Starting warfarin during acute HIT causes a rapid decline in Protein C (a natural anticoagulant), leading to a paradoxical hypercoagulable state and microvascular thrombosis (venous limb gangrene).

Key Concept

Algorithm for the diagnosis and management of Heparin-Induced Thrombocytopenia (HIT)
Rate this question

Topics

Hematology and Oncology

More questions from this topic